Louis Garguilo

ARTICLES BY LOUIS

  • 4/21/2021

    “What’s the USP got to do with it?” That’s what I ask Ronald Piervincenzi, CEO, U.S. Pharmacopeia. The question is triggered by the announcement of a “strategic alliance” between Phlow Technologies and the USP, and the quest to bring advanced manufacturing to our industry.

  • 4/14/2021

    There are extenuating circumstances, but we need a deeper contemplation of what has gone on at Emergent BioSolutions regarding vaccine production. Outsourced Pharma readers are the experienced professionals to do that. So from that lens of supply-chain understanding, what’s happening here?

  • 4/12/2021

    “With regard to the ongoing nature of a relationship with a CDMO, you need to find a partner that can align with your ambition,” says Max Donley, Aurinia Pharmaceuticals. "However," he adds, when a positive drug-sponsor/CDMO relationship starts to deteriorate, "it’s often because the CDMO gets stiff-armed.”

  • 4/8/2021

    Aurinia Pharmaceuticals and Lonza have put together a multi-year agreement for a dedicated manufacturing facility – a state-of-the-art "monoplant” – within the CDMO's existing API facility in Visp, Switzerland. So what exactly is a monoplant? And how can you get one?

  • 4/6/2021

    A biopharma executive believes the industry should receive a more complete rendering of what we’ve learned from our COVID-19 experience.His message is familiar, but isn't sufficiently elucidated: "Our drug development and manufacturing outsourcing model is integral to taming the pandemic."

  • 3/31/2021

    Knut Niss, Chief Technology Officer, Mustang Bio, Inc., has four specific pieces of advice for Outsourced Pharma readers of all stripes, but most specifically targeted at the cell-and-gene therapy developers among you.

  • 3/23/2021

    Knut Niss, Chief Technology Officer, Mustang Bio, Inc., has advice for all cell and gene developers: Build capacity now, outsource as needed later. Perhaps this changes when more CDMOs are set up to serve emerging biopharma. Here's a look.

  • 3/19/2021

    Recent mRNA vaccine successes conceal the long-term challenges emerging mRNA companies have faced with finding experience and capacity at CDMOs. Here’s sound advice for emerging mRNA when forming scientific, investment, and overall plans for commercial success.

  • 3/10/2021

    A Biopharma and CDMO lead a positive nationalism in Canada. In fact, ‘Canada First’ hasn’t the political corollaries felt by “America First” deliberations in the U.S. Jared Davis, CEO of Providence Therapeutics, believes every country should be able to take care of their own during a health-care crises. 

  • 3/3/2021

    An investigation into the amazing story of how an emerging mRNA Biopharma is “enabling” the creation of a CDMO for an “all-Canada” supply chain, for COVID-19 and precision medicines.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.